Compare ATLO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | CRBP |
|---|---|---|
| Founded | 1903 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.2M | 170.3M |
| IPO Year | N/A | N/A |
| Metric | ATLO | CRBP |
|---|---|---|
| Price | $27.38 | $7.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | 36.7K | ★ 162.1K |
| Earning Date | 01-23-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 88.22 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $65,795,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $220.00 |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | ★ 23.09 | N/A |
| 52 Week Low | $16.09 | $4.64 |
| 52 Week High | $28.35 | $20.56 |
| Indicator | ATLO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 74.19 | 41.61 |
| Support Level | $27.06 | $7.33 |
| Resistance Level | $28.35 | $8.23 |
| Average True Range (ATR) | 0.74 | 0.59 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 75.49 | 22.94 |
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.